查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1708018

內分泌檢測市場：全球產業分析、規模、佔有率、成長、趨勢和預測（2025-2032）

Endocrine Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計 2025 年全球內分泌檢測市場價值將達到 134 億美元，到 2032 年將達到 232 億美元，預測期內（2025-2032 年）的複合年成長率為 8.2%。

內分泌檢測市場包括使用各種檢測技術對荷爾蒙失衡和內分泌腺疾病進行分析和診斷。這包括甲狀腺功能、生殖激素、葡萄糖代謝和腎上腺功能的測試。糖尿病、甲狀腺疾病和荷爾蒙癌症等內分泌相關疾病的增加推動了對準確、快速和易於獲取的檢測解決方案的需求。免疫測量和串聯式質譜質譜等診斷方法的技術進步徹底改變了內分泌診斷並改善了臨床結果。

全球內分泌檢測市場受到糖尿病、甲狀腺功能亢進和荷爾蒙失衡等內分泌疾病激增的推動，這些疾病由於久坐的生活方式、壓力和人口老化而呈上升趨勢。人們對早期疾病檢測和定期健康監測的認知不斷提高，導致已開發地區和發展中地區的診斷檢測量顯著增加。診斷技術的進步，例如高通量免疫檢測、質譜和基於生物感測器的方法的整合，進一步提高了檢測的準確性、速度和可負擔性。由於患者對便利性和個人化醫療的偏好，居家醫療和照護現場內分泌檢測的採用率不斷提高，這也是支持市場成長的關鍵因素。

儘管前景樂觀，內分泌檢測市場仍面臨一定的限制因素。先進的診斷平台和專用設備的高成本往往是中低收入地區的一個障礙。此外，由於實驗室間測試準確性的差異和標準化的缺乏，導致診斷結果不一致。新診斷工具的複雜法規和冗長的核准流程也減緩了創新和採用的步伐。此外，許多地區都面臨熟練實驗室技術人員短缺的問題，影響了檢測服務的品質和可靠性。

由於個人化醫療和預測診斷的日益普及，內分泌檢測市場充滿了成長機會。技術創新不斷為下一代測試解決方案打開大門，包括實驗室晶片設備、人工智慧整合診斷系統和多重檢測，可提供更高的靈敏度和更快的周轉時間。新興經濟體，尤其是亞太和拉丁美洲的新興經濟體，由於醫療基礎設施發達且患者意識不斷提高，擁有尚未開發的潛力。診斷公司和醫療保健提供者之間的策略合作夥伴關係正在推動創新並擴大偏遠和服務不足地區進行內分泌檢測的機會。此外，預計家用檢測套組和遠端醫療診斷的興起將在預測期內推動市場大幅擴張。

本報告研究了全球內分泌檢測市場，並按測試、技術、適應症、最終用途、地理位置和公司概況進行細分。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值洞察

第4章全球內分泌檢測市場展望

  • 主要亮點
  • 市場規模分析及預測
    • 2019-2024 年歷史市場規模分析
    • 2025-2032年目前市場規模分析與預測
  • 全球內分泌檢測市場展望（按檢測）
    • 2019 年至 2024 年按測試分類的歷史市場規模分析
    • 2025 年至 2032 年按測試分類的當前市場規模分析與預測
    • 透過測試進行市場吸引力分析
  • 全球內分泌檢測市場技術展望
    • 2019 年至 2024 年按技術分類的歷史市場規模分析
    • 2025 年至 2032 年按技術分類的當前市場規模分析與預測
    • 依技術進行市場吸引力分析
  • 全球內分泌檢測市場展望（按適應症）
    • 2019 年至 2024 年按適應症分類的歷史市場規模分析
    • 目前市場規模分析與預測（按適應症），2025 年至 2032 年
    • 按適應症分析市場吸引力
  • 全球內分泌檢測市場前景（依最終用途）
    • 2019 年至 2024 年按最終用途分類的歷史市場規模分析
    • 目前市場規模分析與預測（依最終用途），2025 年至 2032 年
    • 依最終用途進行市場吸引力分析

5. 全球內分泌檢測市場（按地區）展望

  • 2019 年至 2024 年各地區歷史市場規模分析
  • 2025 年至 2032 年各地區目前市場規模分析與預測
    • 北美洲
    • 拉丁美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 中東和非洲
  • 按地區分析市場吸引力

6. 北美內分泌檢測市場展望

7. 歐洲內分泌檢測市場展望

第8章東亞內分泌檢測市場展望

9. 南亞和大洋洲內分泌檢測市場展望

10. 拉丁美洲內分泌檢測市場展望

第 11 章中東和非洲內分泌檢測市場展望

第12章競爭格局

  • 2025年市場佔有率分析
  • 市場結構
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • Abbott Laboratories, Inc.
    • AB Sciex Pte. Ltd.
    • Agilent Technologies, Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings（LabCorp）
    • Quest Diagnostics, Inc.
    • Thermo Fisher Scientific, Inc.
    • MP Biomedicals
    • Ortho-Clinical Diagnostics（QuidelOrtho Corporation）
    • Siemens Healthineers AG
    • Sysmex Corporation
    • 其他

第13章 附錄

簡介目錄
Product Code: PMRREP35201

Persistence Market Research has recently released a comprehensive report on the global Endocrine Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Endocrine Testing Market Size (2025E): US$ 13.4 Bn
  • Projected Market Value (2032F): US$ 23.2 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Endocrine Testing Market - Report Scope:

The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.

Market Growth Drivers:

The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies-such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods-are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.

Market Restraints:

Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.

Market Opportunities:

The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions-such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays-that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.

Key Questions Answered in the Report:

  • What are the primary factors driving the global endocrine testing market's growth?
  • Which test types and technologies are gaining the most traction among healthcare providers?
  • How are innovations in diagnostic tools impacting endocrine disease management?
  • Who are the major players in the endocrine testing market, and what strategies are they employing?
  • What are the regional trends and long-term projections for the endocrine testing market?

Competitive Intelligence and Business Strategy:

Leading players in the global endocrine testing market-including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche-are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.

Companies Covered in This Report:

  • Abbott Laboratories, Inc.
  • AB Sciex Pte. Ltd.
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.

Market Segmentation:

By Test:

  • Testosterone Test
  • Estradiol Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Luteinizing Hormone (LH) Test
  • Progesterone Test
  • Human Chorionic Gonadotropin (hCG) Hormone Test
  • Insulin Test
  • Others

By Technology:

  • Tandem Mass Spectrometry
  • Immunoassay
  • Monoclonal & Polyclonal Antibody Technologies
  • Clinical Chemistry Analyzers
  • Others

By Disease Indication:

  • Diabetes
  • Hyperthyroidism
  • Menopause
  • Osteoporosis
  • Cancer
  • Others

By End Use:

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Care Centers
  • Home-based Tests
  • Specialty Centers
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Endocrine Testing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Test Adoption / Usage Analysis
  • 3.3. Government Initiatives & Funding in Endocrine Testing
  • 3.4. Key Market Players
  • 3.5. Regulatory Landscape
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis
  • 3.8. Consumer Behavior Analysis

4. Global Endocrine Testing Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Endocrine Testing Market Outlook: Test
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Test, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
      • 4.3.2.1. Testosterone Test
      • 4.3.2.2. Estradiol Test
      • 4.3.2.3. Thyroid Stimulating Hormone (TSH) Test
      • 4.3.2.4. Prolactin Test
      • 4.3.2.5. Luteinizing Hormone (LH) Test
      • 4.3.2.6. Progesterone Test
      • 4.3.2.7. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 4.3.2.8. Insulin Test
      • 4.3.2.9. Others
    • 4.3.3. Market Attractiveness Analysis: Test
  • 4.4. Global Endocrine Testing Market Outlook: Technology
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.2.1. Tandem Mass Spectrometry
      • 4.4.2.2. Monoclonal & Polyclonal Antibody Technologies
      • 4.4.2.3. Clinical Chemistry
      • 4.4.2.4. Immunoassay
      • 4.4.2.5. Others
    • 4.4.3. Market Attractiveness Analysis: Technology
  • 4.5. Global Endocrine Testing Market Outlook: Disease Indication
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
      • 4.5.2.1. Diabetes
      • 4.5.2.2. Hyperthyroidism
      • 4.5.2.3. Menopause
      • 4.5.2.4. Osteoporosis
      • 4.5.2.5. Cancer
      • 4.5.2.6. Others
    • 4.5.3. Market Attractiveness Analysis: Disease Indication
  • 4.6. Global Endocrine Testing Market Outlook: End-use
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
      • 4.6.2.1. Hospitals
      • 4.6.2.2. Diagnotics Laboratories
      • 4.6.2.3. Ambulatory Care Centers
      • 4.6.2.4. Home-based Tests
      • 4.6.2.5. Speciality Centers
      • 4.6.2.6. Others
    • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Endocrine Testing Market Outlook Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Endocrine Testing Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Test
    • 6.1.3. By Technology
    • 6.1.4. By Disease Indication
    • 6.1.5. By End-Use
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 6.3.1. Testosterone Test
    • 6.3.2. Estradiol Test
    • 6.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 6.3.4. Prolactin Test
    • 6.3.5. Luteinizing Hormone (LH) Test
    • 6.3.6. Progesterone Test
    • 6.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 6.3.8. Insulin Test
    • 6.3.9. Others
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.4.1. Tandem Mass Spectrometry
    • 6.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 6.4.3. Clinical Chemistry
    • 6.4.4. Immunoassay
    • 6.4.5. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 6.5.1. Diabetes
    • 6.5.2. Hyperthyroidism
    • 6.5.3. Menopause
    • 6.5.4. Osteoporosis
    • 6.5.5. Cancer
    • 6.5.6. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Diagnotics Laboratories
    • 6.6.3. Ambulatory Care Centers
    • 6.6.4. Home-based Tests
    • 6.6.5. Speciality Centers
    • 6.6.6. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Endocrine Testing Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Test
    • 7.1.3. By Technology
    • 7.1.4. By Disease Indication
    • 7.1.5. By End-use
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 7.3.1. Testosterone Test
    • 7.3.2. Estradiol Test
    • 7.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 7.3.4. Prolactin Test
    • 7.3.5. Luteinizing Hormone (LH) Test
    • 7.3.6. Progesterone Test
    • 7.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 7.3.8. Insulin Test
    • 7.3.9. Others
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.4.1. Tandem Mass Spectrometry
    • 7.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 7.4.3. Clinical Chemistry
    • 7.4.4. Immunoassay
    • 7.4.5. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 7.5.1. Diabetes
    • 7.5.2. Hyperthyroidism
    • 7.5.3. Menopause
    • 7.5.4. Osteoporosis
    • 7.5.5. Cancer
    • 7.5.6. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Diagnotics Laboratories
    • 7.6.3. Ambulatory Care Centers
    • 7.6.4. Home-based Tests
    • 7.6.5. Speciality Centers
    • 7.6.6. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Endocrine Testing Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Test
    • 8.1.3. By Disease Indication
    • 8.1.4. By End-Use
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 8.3.1. Testosterone Test
    • 8.3.2. Estradiol Test
    • 8.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 8.3.4. Prolactin Test
    • 8.3.5. Luteinizing Hormone (LH) Test
    • 8.3.6. Progesterone Test
    • 8.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 8.3.8. Insulin Test
    • 8.3.9. Others
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.4.1. Tandem Mass Spectrometry
    • 8.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 8.4.3. Clinical Chemistry
    • 8.4.4. Immunoassay
    • 8.4.5. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 8.5.1. Diabetes
    • 8.5.2. Hyperthyroidism
    • 8.5.3. Menopause
    • 8.5.4. Osteoporosis
    • 8.5.5. Cancer
    • 8.5.6. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Diagnotics Laboratories
    • 8.6.3. Ambulatory Care Centers
    • 8.6.4. Home-based Tests
    • 8.6.5. Speciality Centers
    • 8.6.6. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Endocrine Testing Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Test
    • 9.1.3. By Technology
    • 9.1.4. By Disease Indication
    • 9.1.5. By End-Use
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 9.3.1. Testosterone Test
    • 9.3.2. Estradiol Test
    • 9.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 9.3.4. Prolactin Test
    • 9.3.5. Luteinizing Hormone (LH) Test
    • 9.3.6. Progesterone Test
    • 9.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 9.3.8. Insulin Test
    • 9.3.9. Others
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.4.1. Tandem Mass Spectrometry
    • 9.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 9.4.3. Clinical Chemistry
    • 9.4.4. Immunoassay
    • 9.4.5. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 9.5.1. Diabetes
    • 9.5.2. Hyperthyroidism
    • 9.5.3. Menopause
    • 9.5.4. Osteoporosis
    • 9.5.5. Cancer
    • 9.5.6. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Diagnotics Laboratories
    • 9.6.3. Ambulatory Care Centers
    • 9.6.4. Home-based Tests
    • 9.6.5. Speciality Centers
    • 9.6.6. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Endocrine Testing Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Test
    • 10.1.3. BY Technology
    • 10.1.4. By Disease Indication
    • 10.1.5. By End-Use
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 10.3.1. Testosterone Test
    • 10.3.2. Estradiol Test
    • 10.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 10.3.4. Prolactin Test
    • 10.3.5. Luteinizing Hormone (LH) Test
    • 10.3.6. Progesterone Test
    • 10.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 10.3.8. Insulin Test
    • 10.3.9. Others
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.4.1. Tandem Mass Spectrometry
    • 10.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 10.4.3. Clinical Chemistry
    • 10.4.4. Immunoassay
    • 10.4.5. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 10.5.1. Diabetes
    • 10.5.2. Hyperthyroidism
    • 10.5.3. Menopause
    • 10.5.4. Osteoporosis
    • 10.5.5. Cancer
    • 10.5.6. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Diagnotics Laboratories
    • 10.6.3. Ambulatory Care Centers
    • 10.6.4. Home-based Tests
    • 10.6.5. Speciality Centers
    • 10.6.6. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Endocrine Testing Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Test
    • 11.1.3. By Technology
    • 11.1.4. By Disease Indication
    • 11.1.5. By End-Use
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 11.3.1. Testosterone Test
    • 11.3.2. Estradiol Test
    • 11.3.3. Thyroid Stimulating Hormone (TSH) Test
    • 11.3.4. Prolactin Test
    • 11.3.5. Luteinizing Hormone (LH) Test
    • 11.3.6. Progesterone Test
    • 11.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 11.3.8. Insulin Test
    • 11.3.9. Others
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.4.1. Tandem Mass Spectrometry
    • 11.4.2. Monoclonal & Polyclonal Antibody Technologies
    • 11.4.3. Clinical Chemistry
    • 11.4.4. Immunoassay
    • 11.4.5. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 11.5.1. Diabetes
    • 11.5.2. Hyperthyroidism
    • 11.5.3. Menopause
    • 11.5.4. Osteoporosis
    • 11.5.5. Cancer
    • 11.5.6. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Diagnotics Laboratories
    • 11.6.3. Ambulatory Care Centers
    • 11.6.4. Home-based Tests
    • 11.6.5. Speciality Centers
    • 11.6.6. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott Laboratories, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. AB Sciex Pte. Ltd.
    • 12.3.3. Agilent Technologies, Inc.
    • 12.3.4. bioMerieux SA
    • 12.3.5. Bio-Rad Laboratories Inc.
    • 12.3.6. DiaSorin S.p.A.
    • 12.3.7. F. Hoffmann-La Roche Ltd.
    • 12.3.8. Laboratory Corporation of America Holdings (LabCorp)
    • 12.3.9. Quest Diagnostics, Inc.
    • 12.3.10. Thermo Fisher Scientific, Inc.
    • 12.3.11. MP Biomedicals
    • 12.3.12. Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
    • 12.3.13. Siemens Healthineers AG
    • 12.3.14. Sysmex Corporation
    • 12.3.15. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations